Mentice has received a €1,062,750 EUR order for simulation solutions from a top 20 global MedTech company.

MAR

Mentice (publ), Gothenburg, a globally recognized leader in simulation solutions for image-guided interventional therapies, announced today that it has secured a significant order valued at €1,062,750 from a top 20 global MedTech company, a long-standing customer of Mentice.

The order includes 15 branded VIST G7 systems for Cardiac Rhythm Management (CRM), emphasizing the company's commitment to enhancing training programs. The advanced simulation aims to improve visibility within this field, addressing challenges such as device selection and procedural accuracy. This investment underscores the importance of comprehensive education and support in fostering trust among healthcare professionals, meeting immediate training needs, and paving the way for growth and innovation in patient care.

Göran Malmberg, CEO of Mentice, commented, “We are proud to further strengthen our collaboration with this esteemed leader in the medical technology field. This order is a testament to the trust our partners place in Mentice's technology to help physicians deliver safer and more effective patient care."


This latest order reflects Mentice’s leading role as a trusted partner for healthcare innovators, providing advanced simulation solutions that improve clinical outcomes and supporting educational initiatives.

The order will be accounted for in the order book for the business area of the Medical Device Industry during the fourth quarter of 2024.  It is anticipated these orders will be delivered during the same quarter.


Mentice definition of a Top 20 Medical Technology company can be found here: https://www.beckershospitalreview.com/innovation/100-largest-medtech-companies.html

Datum 2024-10-31, kl 09:30
Källa MFN
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet